In recent years, a mature anti-trop2 ADC drug named sacituzumab govitecan has been applied in the clinical research of triple-negative breast cancer (Bardia et al., 2019), NSCLC (Heist et al., 2017) and SCLC (Gray et al., 2017) by Goldenberg DM, as well as another anti-trop2 ADC drug named labetuzumab govitecan in colorectal cancer (Dotan et al., 2017). Here, TACSTD2 is linked to small cell lung carcinoma.